Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04463251 at ClinicalTrials.govDocuments that mention this clinical trial
Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale
https://doi.org/10.1186/s12967-021-02828-z
Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment–Elevation Myocardial Infarction (STEMI)
https://doi.org/10.1161/circulationaha.124.069396
- License Information
-
More Information
Article History
Received: 21 January 2021
Accepted: 12 April 2021
First Online: 26 April 2021
Declarations
:
: The study was approved by central and local IRBs in Russia and in the United States.
: None required.
: Dr. Mikhail Samsonov is the Chief Medical Officer of R-Pharm JSC, the developer of RPH-104. Dr. Vlad Bogin is the CEO of Cromos Pharma, LLC, the CRO that is conducting the study. Dr. Van Tassell has received research support from Kiniksa, Novartis, Olatec, Serpin Pharma, Swedish Orphan Biovitrum. Dr. Van Tassell has served as a paid advisor to Cromos Pharma and Serpin Pharma. Dr. Abbate has received research support from Kiniksa, Novartis, Olatec, Serpin Pharma, Swedish Orphan Biovitrum. Dr. Abbate has served as a paid advisor to Cromos Pharma, Eli Lilly, Janssen, Kiniksa, Novo-Nordisk, Olatec, Serpin Pharma.
